Last reviewed · How we verify
Lephetamine (LEFETAMINE)
Lephetamine (generic name: LEFETAMINE) is a lefetamine drug. It is currently in Phase 2 development.
Lefetamine is thought to work by interacting with a specific target in the body, although the exact nature of this interaction is not well understood.
Lephetamine is a small molecule. It is also known as Levetiracetam or Levetiracetam's synonym Levetiracetam's synonym is Levetiracetam, however, another synonym is LEFETAMINA or LEFETAMINE.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LEFETAMINE |
|---|---|
| Drug class | lefetamine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and lefetamine is a key that fits into one of these locks. When it binds to the lock, it can either unlock the cell or block something from getting in. This can affect how the cell works and communicate with other cells, but the details of how it does this are still a mystery.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lephetamine CI brief — competitive landscape report
- Lephetamine updates RSS · CI watch RSS
Frequently asked questions about Lephetamine
What is Lephetamine?
How does Lephetamine work?
What is the generic name of Lephetamine?
What drug class is Lephetamine in?
What development phase is Lephetamine in?
Related
- Drug class: All lefetamine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing